Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Menu

Dipentum 250 Mg Caps 100 By Meda Pharma.

Image 0 of Dipentum 250 Mg Caps 100 By Meda Pharma. Image 1 of Dipentum 250 Mg Caps 100 By Meda Pharma.

Dipentum 250 Mg Caps 100 By Meda Pharma.

CALL US FOR THE PRICE

Dipentum 250 Mg Caps 100 By Meda Pharma. This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXB10151247/RXD5091244/RXA323963
Size : 100
Selling UoM : EA
NDC: 00037-6860-10
UPC Barcode : 300376860100
Supplier: 0050000774 MEDA PHARMACEUTICALS
Supplier Material : 686010
Generic Code : 015514 OLSALAZINE SODIUM ORAL CAPSULE 250 MG
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product Type : BRX Branded RX

Have a question?

  CALL US FOR THE PRICE

Product Description.:

DIPENTUM 250mg
capsule , tan , oblong oblong
Black ink

The active ingredient in DIPENTUM Capsules (olsalazine sodium) is the sodium salt of a salicylate, disodium 3,3'-azobis (6-hydroxybenzoate) a compound that is effectively bioconverted to 5-aminosalicylic acid (5-ASA), which has anti-inflammatory activity in ulcerative colitis.

Olsalazine sodium is a yellow crystalline powder, which melts with decomposition at 240?C. It is the sodium salt of a weak acid, soluble in water and DMSO, and practically insoluble in ethanol, chloroform, and ether. Olsalazine sodium has acceptable stability under acidic or basic conditions.

DIPENTUM is supplied in hard gelatin capsules for oral administration. The inert ingredient in each 250 mg capsule of olsalazine sodium is magnesium stearate. The capsule shell contains the following inactive ingredients: black iron oxide, caramel, gelatin, and titanium dioxide.

INDICATIONS

Olsalazine is indicated for the maintenance of remission of ulcerative colitis in patients who are intolerant of sulfasalazine.
DOSAGE AND ADMINISTRATION

The usual dosage in adults for maintenance of remission is 1.0 g/day in two divided doses.

SIDE EFFECTS

Olsalazine has been evaluated in ulcerative colitis patients in remission, as well as those with acute disease. Both sulfasalazine-tolerant and intolerant patients have been studied in controlled clinical trials. Overall, 10.4% of patients discontinued olsalazine because of an adverse experience compared with 6.7% of placebo patients. The most commonly reported adverse reactions leading to treatment withdrawal were diarrhea or loose stools (olsalazine 5.9% placebo 4.8%), abdominal pain, and rash or itching (slightly more than 1% of patients receiving olsalazine).